R esearch A rticle - British Journal of Medical Practitioners

More documents

Recommendations

Info

British Journal of Medical Practitioners, March 2013, Volume 6, Number 1 therapy. The incidence of hyponatremia secondary to carbamazepine therapy ranges between 4.8 and 40 % depending on the population studied 10,11 . In most cases, hyponatremia is asymptomatic and continuation of the carbamazepine use is possible whilst a close eye is kept on the plasma sodium level 10 . In rare occasions hyponatremia is symptomatic and discontinuation of carbamazepine is warranted. Administration of demeclocycline to normalise the sodium level was suggested by some authors. 12 However, the long term use of demeclocycline is associated with several complications and this approach is hardly a standard practice. Clinicians often face a dilemma when carbamazepine is the only agent able to control a specific clinical problem. With many antiepileptics available, it is unusual to face such a problem in epileptic patients. Trigeminal neuralgia on the other hand can be extremely difficult to control and carbamazepine was found to have a unique ability to manage such unpleasant condition even before its antiepileptic effects were noticed on 1962 13 . Eslicarbazepine is promoted as an alternative to carbamazepine when side effects occurs on otherwise responsive patients to its favourable antiepileptic effects 14 . Hyponatremia is rare in eslacarbazepine users with only an incidence of less than 1% in the small populations studied 15,16 . Frequency of hyponatraemia increased with increasing eslicarbazepine dose. In patients with pre-existing renal disease leading to hyponatraemia, or in patients concomitantly treated with medicinal products which may themselves lead to hyponatraemia 17 . Our patient showed the same favourable response to eslicarbazepine as she experienced with carbamazepine. However, hyponatremia did not occur with eslicarbazepine therapy. This enabled our patient to continue with pharmacological management and avoid surgical interventions. With the exception of epilepsy, no reports are available commenting on the use of eslicarbazepine on the wide range of conditions that carbamazepine is traditionally used for such as mental health problems and neuropathic pain. When patients are well controlled on carbamazepine whatever the indication is, the occurrence of side effects such as hyponatremia is often managed by an automatic replacement with another agent. We feel that in such patients a therapeutic trial of eslicarbazepine might be appropriate especially if the control on carbamazepine was robust or if the benefits of carbamazepine therapy were clearly superior to other pharmacological agents potentially useful for the targeted clinical condition. Competing Interests None declared Author Details TAREK A-Z K GABER, FRCP (London), Consultant in Neurological Rehabilitation, Wrightington, Wigan and Leigh NHS Foundation Trust, UK. MYINT MYINT KYU, MRCP, Specialist Registrar in Rehabilitation Medicine, North West of England Deanery, UK. WAH WAH OO, MRCP, Specialist Registrar in Rehabilitation Medicine, North West of England Deanery, UK. CORRESSPONDENCE: DR TAREK GABER, Consultant in Neurological Rehabilitation, Leigh Infirmary, Leigh, Lancs. WN7 3NF, UK. Email: tgaber@doctors.net.uk REFERENCES 1. Hooge JP, Redekop WK. Trigeminal Neuralgia in Multiple Sclerosis. Neurology 1995; 45: 1294-6 2. Brisman R. Trigeminal neuralgia and Multiple Sclerosis. Arch Neurol. 1987; 44(4):379-381. 3. Zvartau-Hind M, Din MU, Gilani A, Lisak RP, Khan OA. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology 2000; 55(10):1587-8. 4. Gilron I, Booker SL, Rowan JS, Max MB. Topiramate in trigeminal neuralgia: a randomized, placebo-controlled multiple crossover pilot study. Clin Neuropharmacol 2001; 24(2):109-12 5. Khan OA. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology 1998; 51(2):611-4. 6. Leandri M, Lundardi G, Inglese M, Messmer-Uccelli M, Mancardi GL, Gottlieb A, Solaro C. Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis. J Neurol 2000; 247(7):556-8. 7. Cheng JS, Sanchez-Mejia RO, Limbo M, Ward MM, Barbaro NM. Management of medically refractory traigeminal neuralgia in patients with multiple sclerosis. Neurosurg Focus 2005; 18(5):e13 8. Gronseth G, Cruccu G, Argoff C, Brainin M, Burchiel K, Nurmikko T, Zakrzewska JM; American Academy of Neurology Society; European Federation of Neurological Society. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neur. 2008 Oct;15(10):1013-28. 9. Wiffen P, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2000;(2):CD001133. 10. Dong X, Leppik IE, White J, Rarick J. Hyponatremia from Oxcarbazepine and Carbamazepine. Neurology 2005; 65(12): 1976- 1978 11. Van Amelsvoort TH, Bakshi R, Devaux CB, Schwabe S. Hyponatremia Associated with Carbamazepine and Oxcarbazepine Therapy: A Review. Epilepsia 1994; 35(1): 181-188 12. Brewerton TD, Jackson CW. Prophylaxis of carbamazepine-induced hyponatremia by demeclocycline in six patients. The Journal of Clinical Psychiatry 1994; 55(6): 249-251 13. Schindler W, Häfliger F. Über Derivate des Iminodibenzyl. Helvetica Chimica Acta 1954; 37 (2): 472–83. 14. Elger C et al Efficacy & Safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomised, double-blind, placebo-controlled, parallel group, phase III study, Epilepsia, 2009; 50; (3): 453-63. 15. Versavel M et al, An investigation of the effects of eslicarbazepine acetate on hyponatraemia: A pooled analysis of three double-blind phase III clinical studies. Poster presented AES Annual Meeting Dec 2009, San Antonio 16. Nunes T et al. Incidence of rash and hyponatraemia in adult patients with refractory partial seizures treated with adjunctive eslicarbazepine acetate: Results from three phase III studies and 1-year open-label extensions. Poster presented at ECE Annual Meeting June 2010, Rhodes. 17. Gil-Nagel A et al, Efficacy and safety of 800 mg and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures, Acta Neurol Scand, 2009; 120: 281-287. BJMP.org 33
British Journal of Medical Practitioners, March 2013, Volume 6, Number 1 BJMP 2013;6(1):a608 Clinical Practice Irritable Bowel Syndrome for Primary Care Physicians Ali Khanbhai and Daljit Singh Sura Introduction and Epidemiology Irritable bowel syndrome (IBS) is a chronic and often debilitating condition with a complex aetiology 1 . It is the most common diagnosis made by gastroenterologists worldwide 2 . The incidence and prevalence of IBS vary depending on the diagnostic criteria used but it is estimated that the prevalence in the UK is 17% overall, with a prevalence of 11% among men and 23% among women 3-4 . IBS can have a significant negative impact on quality of life and social functioning, although it is not known to be associated with the development of serious disease or excess mortality. However, patients with IBS are more likely to undergo specific surgical operations such as hysterectomy and cholecystectomy. IBS further represents an economic burden on society due to the high consumption of healthcare resources and the non-productivity of IBS patients 5 . It appears that 33–90% of patients do not consult a physician, and that a proportion of patients who meet the IBS criteria are not diagnosed with IBS. The frequency of IBS symptoms peaks in the third and fourth decades, and there is a female predominance of about 2:1 in the 20s and 30s, although this discrepancy is less apparent in older patients 6 . The female predominance is less apparent in the general population, which suggests that women with IBS are more likely to seek healthcare for their symptoms 7 . IBS symptoms which persist beyond middle life continue to be reported by a substantial proportion of individuals in their seventh and eighth decades. Pathogenesis The pathogenesis of IBS appears to be multifactorial. The following factors play a central role in the pathogenesis: heritability and genetics, dietary and intestinal microbiota, lowgrade inflammation and disturbances in the neuroendocrine system of the gut 2 . IBS is known to aggregate in families and to affect multiple generations but not in a manner consistent with a major Mendelian effect. Relatives of an individual with IBS are two to three times as likely to have IBS 8 . Psychological distress is not only a common co-morbidity in IBS patients, but also a factor which is likely to play a direct role in the pathogenesis 4 . Interestingly, parental modelling and the reinforcement of illness behaviour can also contribute to IBS. Having a mother with IBS has been shown to account for as much variance as having an identical set of genes as a co-twin who has IBS. This insinuates that the contribution of social learning to IBS is at least as great as the contribution of heredity. Furthermore, the role of childhood events such as nasogastric tube placement, poor nutrition, abuse, and other stressors have been clearly associated with IBS 8 . A substantial proportion of patients with IBS report onset of their symptoms after acute gastroenteritis 9 . Post-infectious (PI)- IBS has been reported after viral, bacterial, protozoa and nematode infections, with the incidence of PI-IBS varying between 7% and 31%. In this subset of IBS patients GI symptoms appear following gastroenteritis, with approximately 10% developing persistent symptomsRecent studies suggest that some individuals are genetically predisposed to developing PI- IBS, with some people demonstrating a specific cytokine response to infection 4 . It is important to note that women appear to have more frequent and severe IBS symptoms during menses compared to other phases of the menstrual cycle and that female gender is a significant independent risk factor for the development of IBS 7 . Diagnosis and Investigations Adult patients who present to their general practitioner (GP) with lower gastrointestinal tract disorders account for one in 20 of all general practice consultations. The possibility of sinister conditions such as colorectal cancer or inflammatory bowel disease may create diagnostic uncertainty and reluctance for the doctor to attribute the symptoms to IBS. In the United Kingdom up to 29% of patients with IBS are referred to a specialist but the majority of these will return to their GP for long term management 6 . Primary care differs from specialist care because the GP’s greater familiarity with the patient, and their previous consultations, enable presenting problems to be seen in context rather than in isolation. Furthermore, it involves the first contact for care of problems at a stage when they are likely to be poorly defined. Lastly, primary care is characterised by a biopsychosocial model of care that takes into account the context of the person’s BJMP.org 34
Page 1 and 2: BJMP Volume 6 Number 1 March 2013 B
Page 3 and 4: • Dr Mohammed Azher, Consultant P
Page 5 and 6: British Journal of Medical Practiti
Page 33: British Journal of Medical Practiti

R esearch A rticle - British Journal of Medical Practitioners

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?